Change of Registered Office and Principal Place of Business Address

28 May 2024: PharmAust Limited (ASX: PAA & PAAOA) ("PharmAust" or "the Company") wishes to advise that its registered office and principal place of business address will change with immediate effect to:

Level 4
96-100 Albert Road
South Melbourne VIC 3205

The Company's telephone number has also changed to: +61 3 9692 7222

All other details remain unchanged.

This announcement is authorised for release by the Board of Directors of PharmAust Limited.

For further information, please contact:

John Clark
Managing Director
investorenquiries@pharmaust.com

P: +61 (3) 9692 7222
W: www.pharmaust.com

Media:
Matthew Wright
NWR Communications
matt@nwrcommunications.com.au
0451 896 420

About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (ASX Code: PAA). PAA is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases.

MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in the growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular "cleaning process," where toxic protein is broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including motor neuron disease (MND/ALS).

PAA's lead MPL program is for the treatment of MND/ALS, a rare, incurable disease. The company recently announced positive top-line results for its Phase 1 study in patients with MND/ALS. PAA anticipates commencing enrolment in its pivotal registration adaptive Phase 2/3 clinical study in H2 CY 2024 that could lead to accelerated approval with the US Food and Drug Administration in 2026.

The Neurodegenerative Disease Market size is estimated at USD 55.12 billion in 2024, and is expected to reach USD 77.82 billion by 2029, growing at a CAGR of 7.14% during the forecast period (2024-2029).[1]

[1] https://www.mordorintelligence.com/industry-reports/neurodegenerative-disease-market

PharmAust Investor Hub:

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning PharmAust. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

Access the investor hub by scanning the QR code or visiting:
https://investorhub.pharmaust.com/